381 Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: the phase 1b MITCI study

• Kim Margolin,
• Robert HI Andtbacka,
• Carlo Bifulco,
• Gregory Daniels,
• Sigrun Hallmeyer,
• Mark Grose,
• Jon Richards,
• Mark Faries,
• Yiwei Zhang,
• John Hyngstrom,
• Lynn Feun,
• Anlong Li

Affiliations

Kim Margolin

Medical Oncology, City of Hope National Medical Center and Comprehensive Cancer Center, Duarte, California, USA

Robert HI Andtbacka

Aff3 grid.412722.00000000405153663Huntsman Cancer Institute Salt Lake City UT USA

Carlo Bifulco

Providence Cancer Institute, Portland, Oregon, USA

Gregory Daniels

3University of California, La Jolla, CA, USA

Sigrun Hallmeyer

Aff3 grid.477670.5Oncology Specialists SC Park Ridge IL USA

Mark Grose

Aff145 grid.417993.10000000122600793Merck & Co., Inc. Kenilworth NJ USA

Jon Richards

Aff433 grid.477670.5Oncology Specialists, S.C. Niles IL USA

Mark Faries

2John Wayne Cancer Institute, Los Angeles, CA, USA

Yiwei Zhang

Aff3 0000 0000 2220 2544grid.417540.3Lilly Research Laboratories, Department of Biologics Technology New York NY USA

John Hyngstrom

Huntsman Cancer Institute Cancer Hospital, Salt Lake City, Utah, USA

Lynn Feun

1University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, USA

Anlong Li

9Merck and Co., Inc., Kenilworth, NJ, USA